Aktis Oncology, Inc. (AKTS) return on equity (ROE)

Return on equity · fiscal 2021
-37.6%

Aktis Oncology, Inc. (AKTS) earned a return on equity of -37.6% in fiscal 2021 (the year ended June 30, 2021). That is 49.5 percentage points higher than the -87.1% of fiscal 2020. Figures as of 17 Nov 2026, 23:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2021
-37.6%
Change on fiscal 2020
+49.5 pts
Highest on record
-29.2%fiscal 2015
Lowest on record
-292.8%fiscal 2014
Fiscal years on record
92014–2021

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Aktis Oncology, Inc. return on equity (ROE), in more detail

Across the 9 fiscal years on record (2014–2021), the highest was -29.2% in fiscal 2015 and the lowest -292.8% in fiscal 2014. The fiscal 2021 figure is higher than in 88% of the 8 earlier fiscal years on record, whose median is -133.4%.

History · 9 fiscal years

Return on equity by fiscal year

Aktis Oncology, Inc. return on equity (ROE), year by year

Aktis Oncology, Inc. (AKTS) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2021-37.6% 49.5 pts up
2020-87.1% 25.6 pts up
2019-112.7% 44.3 pts up
2018-157.0% 91.5 pts down
2017-65.5% 136.5 pts up
2016-202.0%—
2016-154.2% 125.0 pts down
2015-29.2% 263.6 pts up
2014-292.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on AKTS

Aktis Oncology, Inc., figure by figure

Aktis Oncology, Inc. (AKTS) overview: price, valuation and scorecard

Aktis Oncology, Inc. return on equity (ROE): questions and answers

What is Aktis Oncology, Inc.'s return on equity?

Aktis Oncology, Inc. (AKTS) earned a return on equity of -37.6% in fiscal 2021 (the year ended June 30, 2021). That is 49.5 percentage points higher than the -87.1% of fiscal 2020.

Is Aktis Oncology, Inc.'s return on equity high or low compared with its own history?

The fiscal 2021 figure is higher than in 88% of the 8 earlier fiscal years on record, whose median is -133.4%.

What are the highest and lowest return on equity figures on record for Aktis Oncology, Inc.?

Across the 9 fiscal years on record (2014–2021), the highest was -29.2% in fiscal 2015 and the lowest -292.8% in fiscal 2014.

How is Aktis Oncology, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Aktis Oncology, Inc. (AKTS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/AKTS/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.